29 May 2017
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the appointment of Alexander Kuzin to the post of General Director (CEO). This decision has taken unanimously by the Board of Directors of NovaMedica on May 26, 2017.
Alexander Kuzin is a professional with more than 20 years of experience in the pharmaceutical market. He has been a managing director at “RMI Partners” for two years. It controls “RusnanoMedInvest” venture fund (RMI, a subsidiary of RUSNANO), including one of its largest investment projects NovaMedica.
Over the past five years Rusnano and Domain Associates, as well as RMI Partners, have created a bright ambitious company NovaMedica, which promotes innovative developments from the RMI venture capital portfolio and has already started creating a number of its own R&D drugs. In April 2017 NovaMedica opened an innovative Technology Center, in launching of which Moscow mayor Sergei Sobyanin took part. In 2016 NovaMedica became a strategic partner of Pfizer – one of the largest pharmaceutical companies in the world. The professional community recognized this cooperation as the deal of the year in the contest of the national industry prize “Platinum ounce”. On May 30, NovaMedica starts a construction of an injection pharmaceutical plant in the Kaluga region, where more than 30 life-saving and essential for Russia drugs from Pfizer's portfolio will be produced. The last two years Alexander Kuzin actively participated in the development of NovaMedica having earned the respect of colleagues and shareholders.
Anatoly Chubais, Chairman of the Executive Board of Managing Company “RUSNANO” and Chairman of the Board of Directors of NovaMedica:
“We are proud of this project, NovaMedica is an important part of the portfolio of the fund “RusnanoMedInvest”. One of the brightest innovative pharmaceutical companies in Russia has been built from scratch under the management of RMI Partners during 5 years, and we are grateful to RMI Partners for this. We know Alexander Kuzin firsthand and sincerely wish him success. We are very pleased that the internal candidate has come to the first position and that we are able to grow the strongest staff in NovaMedica and create continuity in management”.
Tatyana Saribekyan, CEO of Domain Russia Investments and Member of the Board of Directors of NovaMedica:
“Domain Associates is one of the first and largest venture capital funds in the life science sector in the world. We have invested to the development of NovaMedica our experience of several decades and we are very proud that with our help NovaMedica has grown into a serious, promising and dynamically developing company and has become a key partner of Pfizer, one of the largest companies in the global pharmaceutical market”.
Alexander Kuzin, CEO of NovaMedica:
“I am grateful to shareholders and RMI Partners for their comprehensive support and trust. I really love this project and I think it is of fundamental importance to fulfill all the tasks set before me and the team of NovaMedica. Overcoming of ever higher bars gives a feeling of drive and moves forward. I am sure that NovaMedica will become one of the key players in the new Russian pharma. I dream of making progress for the benefit of NovaMedica, its shareholders and our country”.
The position "General Director" is introduced for the first time in the company..
NovaMedica is a modern Russian pharmaceutical company founded in 2012 by Domain Associates LLC, leading U.S. venture capital firm, and RUSNANO, JSC (RUSNANO controls 50% of NovaMedica shares through the venture fund RusnanoMedInvest). NovaMedica's strategy is aimed at search, registration and localization in Russia of intellectual property rights for innovative pharmaceuticals products and technologies, as well as at development and implementation of own R&D projects.
NovaMedica owns intellectual property rights within Russia and the CIS on innovative developments from the portfolio of the RusnanoMedInvest venture fund. Today NovaMedica’s pipeline already has 36 IP for preparations for antiviral and anti-inflammatory therapy, treatment of ophthalmic diseases and epilepsy, innovative technologies for detection of oncological and infectious diseases. Also NovaMedica is working on creation of a number of its own products. R&D department of the company plans to develop about 15 innovative drugs until 2022. These are drugs for treatment of diseases in the field of gastroenterology, pain management, neurology, ophthalmology and rheumatology.
In April 2017 NovaMedica opened the Technological Center with a complex of R&D laboratories and pilot production in Technopolis “Moscow”. The Technological Center has the latest technological capabilities previously unavailable in the Russian pharmaceutical industry. The company also has a developed infrastructure for promoting and selling pharmaceutical products.
Contacts for media: Tatiana Albaut , +79175451241
RUSNANO Joint-Stock Company was founded in March 2011 through reorganization of state corporation Russian Corporation of Nanotechnologies. JSC RUSNANO contributes to implementation of the state policy on the development of the nanotechnology industry by investing directly and through investment funds of nanotechnology in financially effective high-technology projects providing the development of new production facilities in the Russian Federation. Its primary investment focus is in electronics, optoelectronics and telecommunications, healthcare and biotechnology, metallurgy and metalwork, energy, mechanical engineering and instrument making, construction and industrial materials, chemicals and petrochemicals. 100 percent of shares of JSC RUSNANO are owned by the state. Thanks to investments RUSNANO currently opened 73 factories and R&D centers in 28 regions of Russia.
Management of assets of RUSNANO JSC is carried out by Limited Liability Company established in December 2013, RUSNANO Management Company. Anatoly Chubais is the Chairman of its Executive Board.
Work to establish nanotechnology infrastructure and carry out educational programs is fulfilled by RUSNANO’s Fund for Infrastructure and Educational Programs, which was also established during the reorganization of the Russian Corporation of Nanotechnologies. More information at www.rusnano.com Contacts: 10A, prospect 60-letiya Oktyabrya, Moscow, Russia 117036. Phone +7 (495) 988-5677, Fax +7 (495) 988-5399, e-mail: email@example.com.
RMI Partners is a venture capital company established in 2012, with a strategic focus on investments supporting the development of innovative biopharmaceutical products and medical technologies. In Eastern Europe and Russia, RMI Partners is one of the largest investors in life sciences. The company makes global investments in a variety of therapeutic areas.
RMI Partners brings together an international team of professionals with many years’ unique experience in the field of venture capital business, entrepreneurship, and life sciences industry. Our relationship with portfolio companies based on the principles of mutually beneficial cooperation. We use all our experience and knowledge to support and develop our partners’ ideas, and we are proud to participate in the creation of revolutionary products promoting better health for large numbers of people.
RMI Partners is currently managing the venture fund RusnanoMedInvest (RMI, a subsidiary of JSC RUSNANO), which was created in 2012 to develop innovative projects in the field of medicine and pharmaceutics. RMI’s portfolio includes companies from Russia, USA, UK and Israel, specializing in the development and marketing of innovative pharmaceutical and medical technologies, many of which successfully completed an initial public offering (IPO) on NASDAQ, or were purchased by strategic buyers.
The Russian pharmaceutical company NovaMedica is a key company in RusNanoMedInvest’s portfolio. With NovaMedica, RMI promotes the transfer of know-how and intellectual property rights to its portfolio companies’ developments to Russia, in order to implement and promote them in the Russian market. NovaMedica’s strategy targets the research, registration and Russian localization of intellectual property rights for innovative products and technologies, the development and implementation of its own R&D projects, as well as the creation of a modern R&D center and high-tech pharmaceutical GMP production.
RMI Partners is a member of Invest Europe, the association which is representing Europe’s private equity, venture capital and infrastructure sectors. RMI Partners is an international team of professionals with a unique long-term experience in the field of venture business, entrepreneurship and creating their own projects. Our relations with portfolio companies are based on the principles of mutually beneficial cooperation. We invest all our experience and knowledge in supporting and developing the ideas of our partners and are proud of the opportunity to participate in the creation of revolutionary products for human health. More details – rmivc.com.
Domain Ruissia Investment -is a company founded by Domain Associates LLC for promotion of innovative developments and technologies in the field of pharmaceuticals on the Russian market. DRI plays an important role in cooperation between Domain Associates and RUSNANO participating in the process of transfer of intellectual property rights to innovative drugs and technologies for their production in Russia.
Domain Associates - is an American company founded in 1985; it is one of the most recognized management companies of venture funds specializing in creation of medical products and technologies. More than 260 projects have been created and financed during its existence. Currently assets worth $ 2.7 billion are under the management of Domain Associates, and the investment portfolio consists of more than 50 companies. The company's main offices are in Princeton (New Jersey) and San Diego (California).
Domain Associates focuses on three investment segments: pharmaceuticals, development of special drugs and development of medical equipment, while the additional sphere of the company's interests includes development of biomaterials, medical and biological equipment and diagnostics.
Domain Associates invests mainly in new areas of Life Science with great business growth potential, looking for companies with outstanding technological developments aimed at areas of medicine with a potentially large market, in which there is unmet demand, problems that do not have a solution. This is the key to successful investment management. More information – www.domainvc.comPrint
11 December 2019
11 December 2019
10 December 2019
10 December 2019